18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis
- 295 Downloads
Angiotensin-converting enzyme (ACE) and soluble interleukin-2 receptor (sIL-2R) are serological markers, widely used for determining sarcoidosis activity. 18F-FDG PET has proven to be a sensitive technique in the imaging of sarcoidosis. The aim of this study was to determine sensitivity of 18F-FDG PET, genotype-corrected ACE and sIL-2R in active sarcoidosis as well as their correlation.
This retrospective study included 36 newly diagnosed, symptomatic sarcoidosis patients. ACE and sIL-2R levels were simultaneously obtained within 4 weeks of 18F-FDG PET. ACE was corrected for genotype and expressed as Z-score. 18F-FDG PET was visually evaluated and scored as positive or negative. Maximum and average standardized uptake values (SUVmax and SUVavg) were compared with ACE and sIL-2R.
18F-FDG PET was found positive in 34 of 36 patients (94%). Thirteen patients (36%) showed an increased ACE with the highest sensitivity found in patients with the I/I genotype (67%). Seventeen patients (47%) showed an increased sIL-2R. No correlation was found between SUV and ACE or sIL-2R. Increased ACE and sIL-2R correlated with a positive 18F-FDG PET in 12 patients (92%) and 16 patients (94%), respectively.
18F-FDG PET is a very sensitive technique to assess active sarcoidosis, in contrast with ACE and sIL-2R, suggesting a pivotal role for 18F-FDG PET in future sarcoidosis assessment.
Keywords18F-FDG PET Angiotensin-converting enzyme Soluble interleukin-2 receptor Sarcoidosis
- 17.Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736–55.Google Scholar
- 18.Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008;35:2320–33. doi: 10.1007/s00259–008–0874–2.PubMedCrossRefGoogle Scholar